June round-up of pharma/biotech M&A activity

The Brexit risk and reality, and the beginning of the summer slow-down might explain why June was a quieter month than May in pharmaceutical industry deal-making.

That does not mean there have been some deals done and further rumors and posturing over potential takeovers, such as continued news on the $9.3 billion bid from French pharma major Sanofi (Euronext: SAN) of US biotech Medivation (Nasdaq: MDVN), and reports that  Ireland-headquartered Perrigo (NYSE: PRGO) was to be bought by a UK-based company.

There has also been the continuing divestment of assets of Israel's Teva Pharmaceutical Industries (NYSE: TEVA) to satisfy the conditions of its $40.5 billion purchase of the generics business of Ireland-incorporated Allergan (NYSE: AGN), with Impax Laboratories USA-based Impax Laboratories (Nasdaq: IPXL) buying a range of products in a $586 million deal. These are not included as actual M&A deals, since thet are only asset purchases.